Revenue and earnings growth ahead of plan 2 0 2 4 I N T E R I M R E S U L T S 5 Key financials • Interim result ahead of Company plan- Revenue growth of 3.7% to $812.1 million- EBITDA up 5.0% to $113.2 million with an EBITDA margin of 13.9% (up 0.2ppts)- Net profit after tax (NPAT) attributable to owners of the Company up 15.6% to $85.3 million1- Basic earnings per share (EPS) up 18.6% to 11.8 cents- Closing net cash2 of $792.1 million up $34.9 million on June 2023 with operational cash conversion of 86.8%3 • Revenue growth driven by China segment (China label + CBEC)- China & Other Asia segment sales up 16.5%, ANZ sales down 24.1% due to a change in distribution strategy, USA sales up 8.6% and MVM sales down 4.7%- Total IMF sales up 1.5% with China label sales up 10.4% and English label sales down 6.9%- Liquid milk sales in ANZ and USA up 1.5% and 7.0% respectively- Other nutritionals up 48.5%
